News 
Market Data 
Discover
Replies to post #6718 on Novavax Inc (NVAX)
06/27/19 7:56 AM
06/27/19 8:08 AM
“The accelerated approval pathway, combined with the strategic partnership we announced today with Catalent Biologics, allow us to efficiently and cost effectively complete the clinical development of NanoFlu through BLA and licensure,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “The Catalent deal provides an $18 million cash infusion and flexible manufacturing capacity, supported by the experienced professionals transferred from Novavax to Catalent.”
